“…GSK3 acts a potent driver of inflammation, rendering GSK3 inhibitors a promising target of anti-inflammatory research [17,121]. It is well established that enzymatically active GSK3 acts as a crucial positive regulator of pro-inflammatory cytokines (e.g., TNF, interleukin (IL-)1β, IL-6 [15], IL-17, IL-18 [122], IL-23 [94], IL-12, IFN-γ [17]), chemokines (IL-8 [122], C-C motif chemokine ligand (CCL) 2 [17], 3, 4 [123], and 12, C-X-C motif chemokine ligand (CXCL) 1, 2, 5 [17], and 10 [124]), and further pro-inflammatory mediators (e.g., nitric oxide (NO) [125] or prostaglandin E2 [126]). Vice versa, anti-inflammatory cytokines, such as IL-2 [127], IL-10 [90], IL-22 [128], IL-33 [129], and IL-1 receptor antagonist [130], are negatively regulated by GSK3.…”